FATE Fate Therapeutics, Inc.
USHealthcareAs of 2026-07-08 16:00
Why FATE matters now
Fate Therapeutics, Inc. (FATE) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.93 with -2.98% on the session and $341.5M in market capitalization; recent performance reads 1-month +10.58% and YTD +112.70%.
The latest financial table shown here is Q1 2026, with revenue of $1.3M, net income of $-31.2M, and EPS of $-0.26. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -44.4%.
The latest indexable market news headline is "Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $5.50; recent insider activity includes Hamill Laura filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.40
P/S
38.57
EV/EBITDA
-2.39
DCF Value
$-0.44
FCF Yield
-44.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-415.8%
Operating Margin
-2207.5%
Net Margin
-2056.8%
ROE
-58.9%
ROA
-45.6%
ROIC
-53.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.3M | $-31.2M | $-0.26 |
| Q4 2025 | $1.4M | $-32.4M | $-0.27 |
| FY 2025 | $6.6M | $-136.3M | $-1.15 |
| Q3 2025 | $1.7M | $-32.3M | $-0.27 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$5.50
Target (Median)
$5.50
Target Range
$4.00 - $7.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.52
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.